Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression

Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce. We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients with mild to moderate breakthrough COVID-19 treated with molnupiravir between January 2022 and February 2022....

Full description

Bibliographic Details
Main Authors: Antonio Vena, Luca Traman, Martina Bavastro, Alessandro Limongelli, Chiara Dentone, Federica Magnè, Daniele Roberto Giacobbe, Malgorzata Mikulska, Lucia Taramasso, Antonio Di Biagio, Matteo Bassetti
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
molnupiravir
COVID-19
vaccines
Intensive care unit admission
Online Access:https://www.mdpi.com/2076-393X/10/7/1141

Internet

https://www.mdpi.com/2076-393X/10/7/1141

Similar Items